Stay updated on SAGE-217 Safety in MDD Insomnia Clinical Trial
Sign up to get notified when there's something new on the SAGE-217 Safety in MDD Insomnia Clinical Trial page.

Latest updates to the SAGE-217 Safety in MDD Insomnia Clinical Trial page
- Check6 days agoChange DetectedThe sponsor of the study changed from Sage Therapeutics to Biogen, and Biogen is now listed as the sponsor and responsible party. Related sections such as the official title and sponsor information reflect Biogen’s involvement.SummaryDifference0.4%

- Check13 days agoNo Change Detected
- Check35 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference2%

- Check42 days agoChange DetectedAdded a new version tag (v3.1.0) and removed several drug-safety topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) from the page.SummaryDifference0.2%

- Check56 days agoChange DetectedVersion bumped from v3.0.1 to v3.0.2 and the Back to Top element was removed. No substantive changes to core content, pricing, stock, or time-related information.SummaryDifference0.1%

- Check63 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, and a 'Back to Top' feature has been added.SummaryDifference0.1%

- Check70 days agoChange DetectedThe web page has updated its facility name and location details, specifically highlighting St. Louis, Missouri, and added drug information for zuranolone, while removing previous references to depression and related terms.SummaryDifference2%

Stay in the know with updates to SAGE-217 Safety in MDD Insomnia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SAGE-217 Safety in MDD Insomnia Clinical Trial page.